Association of Post-Acute Sequelae of COVID-19 with respiratory system diagnoses: a population-based case-control study of Region Stockholm.

Running title: Post-Acute Sequelae of COVID-19 and respiratory system illnesses

Pia Lindberg, RN^{1,2}*; Gunnar Ljunggren, MD, PhD^{3,4}, Seika Lee MD^{3,5}; Iryna Kolosenko, PhD¹; Michael Runold, MD, PhD^{1,2}; Kristina Piontkovskaya MD, PhD^{1,2}; Caroline Wachtler, MD, PhD³; Artur Fedorowski, MD, PhD⁶, Axel C. Carlsson^{3,4 §}, PhD and Åsa M. Wheelock, PhD^{1,2 §}

¹ Division of Immunology and Respiratory Medicine, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

² Department of Respiratory Medicine and Allergy, Karolinska University Hospital Solna, Solna, Sweden.

³ Division for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.

⁴ Academic Primary Health Care Centre, Region Stockholm, Sweden.

⁵ Occupational and environmental medicine, Medical Sciences, Uppsala University, Uppsala, Sweden.

⁶ Department of Cardiology, Karolinska University Hospital, and Department of Medicine, Karolinska Institutet, Stockholm, Sweden

[§] Contributed equally *Corresponding author: Pia Lindberg, Respiratory Medicine Unit, Dept. of Medicine Solna and center for Molecular Medicine, Karolinska Institutet, Solnavägen 30, Bioclinicum Lungforskningslab, J7:30, 17174 Solna, Sweden. Pia.lindberg@ki.se +46 702 645 854

Word count: 2398 Number of Figures: 2 Number of Tables: 2 Supplemental Digital Content files: 1 (.docx)

ABSTRACT

Objectives:

Post Acute Sequelae of COVID-19 (PASC) is an important health concern after the COVID-19 pandemic. We aimed to investigate the prevalence of respiratory system disorders before and after the pandemic onset in individuals with and without PASC.

Methods:

We designed a case-control study was designed to investigate the prevalence of respiratory system-related diagnoses in adult, non-hospitalized PASC patients (cases) in 2019, 12 months before and 6 months after the PASC diagnosis compared to matched controls without PASC. Data was extracted from the Stockholm Region's database warehouse (VAL).

Results:

Higher diagnostic rates for common respiratory illnesses were observed among PASC patients in 2019 and 12 months before PASC diagnosis, which then slightly decreased 6 months after PASC diagnosis. PASC patients showed more pre-pandemic respiratory diagnoses compared to controls: in 2019 they had higher incidence of acute upper respiratory tract infection (OR 2.47 for males, 2.22 for females), asthma (OR 1.76 (males), 1.95 (females)), and bronchitis (OR 2.15 (males), 2.71 (females)) compared to controls.

Conclusions:

This study highlights that individuals with PASC have a higher prevalence of respiratory disorders both before and after their COVID-19 diagnosis. Notably, asthma and other respiratory conditions were more common in PASC patients compared to matched controls. Our study demonstrates that individuals with asthma are more likely to develop PASC, even if asthma does not increase the severity of acute COVID-19. These findings underscore the need for further investigation into the underlying mechanisms connecting respiratory illnesses and PASC. Understanding the long-term consequences of COVID-19 in individuals with pre-existing conditions will be crucial for refining clinical management strategies and improving patients outcomes.

Keywords

Post-Acute Sequelae of SARS-CoV-2 Infection (PASC); Case Control Studies; Signs and Symptoms, Respiratory; Somatic Symptoms; Symptom Cluster; Neurobehavioral Signs and Symptoms; Primary Healthcare; Diagnosis

List of abbreviations

PASC - Post Acute Sequelae of COVID-19, VAL - Stockholm Regional Health Care Data Warehouse; ICD-10 - International Classification of Diseases, 10th edition; OR - odds ratio; CI - confidence interval.

INTRODUCTION

Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also referred to as post-acute Sars-CoV-2 syndrome (PACS), post-COVID, or long-COVID (1-5) is a new diagnosis with a spectrum of diverse persistent symptoms involving multiple organ systems. PASC is defined by symptoms associated with SARS-Cov-2 infection such as chronic cough, chest pain, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in libido and sexual capacity, loss of change in smell or taste, thirst, and abnormal movements persisting 3 months after the primary infection. In Autumn 2020, WHO introduced a first definition and a diagnostic code for Post COVID-19 condition, unspecified (6). In 2021, a Delphi process was conducted to provide consensus guidelines for diagnosis of Post COVID (7, 8). This consensus specifies that symptoms of the syndrome can be diverse and persist for at least three months, can fluctuate in intensity over time and cannot be attributed to any other diagnosis. The risk factors and mechanisms associated with PASC remain uncertain, and it is unlikely that a single factor accounts for the wide range of symptoms affecting different organ systems. At this point it is evident that PASC is an umbrella diagnosis composed of multiple sub phenotypes, each influenced by distinct risk factors, biological mechanisms, and disease courses. Various elements, such as genetics, age, gender, pre-existing health conditions, microbiome composition, and viral traits, may trigger different pathological responses (9).

Similarities between PASC and post-intensive care syndrome (PICS) symptoms, and the higher prevalence of PASC in individuals who received intensive care for severe COVID-19 in during the acute infection initially led to the theory that these symptoms primarily represented sequelae of intensive care, which is common also following ICU visits for other conditions (10). However, a range of studies have indicate a wide variation in prevalence for PASC. Some studies show a prevalence around 10% among non-hospitalized patients with a mild infection who also experience PASC (1, 3). Longitudinal studies suggest that up to 46% of patients have persistent symptoms 12 months after a non-severe COVID-19 infection (11, 12). A review by Davies et al. noted that PASC affects individuals across all age groups regardless of the severity of the acute phase (4). However, the highest incidence of PASC is seen in those between 36 and 50 years of age, with most cases occurring in non-hospitalized patients who had a mild form of the initial infection (4).

In this study, we aimed to investigate the prevalence of respiratory symptoms and disorders in non- hospitalized subjects with a PASC diagnosis pre- and post-primary SARS-CoV-2

infection, extracted from population registries at the time points pre-pandemic (2019), 12 months before, and 6 months after PASC diagnosis.

METHODS

Study Database

The Stockholm County Healthcare Region (Stockholm Region) provides healthcare services under the governance of the Stockholm Region. With approximately 2.5 million residents, the Stockholm Region is the largest in Sweden, covering a variety of urban and rural areas. Healthcare is meticulously documented in the Stockholm Regional Health Care Data Warehouse (VAL), with a documented credibility through contribution to national health registers and benchmarking reports (13). Since 1997, diagnoses have been systematically coded according to the World Health Organization's International Classification of Diseases, 10th revision (ICD-10), ensuring standardization and consistency in healthcare data management (6). The authors had access to all diagnoses, healthcare visits at all care levels in the Region, both primary and specialist care.

Study Population

In this Case-Control study, the cohort comprised adults 18 years of age and older residing in the Stockholm Region for the entire duration of the study, January 2019 to February 2022. Individuals who relocated in or out of the region or died during this period were excluded. The inclusion criteria for PASC patients (cases) were post-COVID-19 diagnosis U09.9 (ICD-10) obtained for the first time between January 1 and December 31 2021 in primary or specialized healthcare settings. Individuals who were hospitalized during the acute phase of COVID-19 were excluded.

Each case was matched with 10 controls based on age, sex, and neighborhood socioeconomic status, based on the date when cases obtained their PASC diagnosis. Diagnostic codes for symptoms and conditions related to post-COVID with respiratory involvement were extracted (3,4) from three timepoints: diagnoses recorded during 2019, 12 months prior to PASC diagnosis, as well as 6 months after the date of U09.9 diagnosis for both cases and their ten matched controls. Since access to data from the registry was limited until February 10, 2022, the 6-month post-PACS diagnostic timepoint was shorter for some study subjects (minimum of 40 days). The study design is illustrated in Figure 1.

Diagnoses

ICD-10 diagnoses applied in this study are presented in Supplementary Table 1 (6). In brief, the diagnosis code for PASC is U09.9, post COVID-19, and the respiratory diagnoses investigated include acute upper respiratory tract infection (J06.9), acute bronchitis (J20.9, J40.9), asthma (J45.1, J45.8, J45.9, J46.9), cough (R05), dyspnea (R06.0) and other and unspecified respiratory disorders (R06.8).

Neighborhood socioeconomic status

The Mosaic tool was utilized to categorize various municipalities and regions within the area based on socioeconomic status. Originally designed to optimize sales efficiency, Mosaic has demonstrated credibility in epidemiological studies due to its ability to generate multivariable models, encompassing over 400 variables. Through the utilization of Mosaic, three levels of socioeconomic status—high, medium, and low—were delineated (14, 15).

Ethical approval

Ethical approval was obtained from the Swedish Ethical Review Authority (Case no. 2021-01016 and 2021-05735).

Statistical methods

Conditional logistic regression was used to calculate odds ratios (OR) with 99% confidence intervals (CI) for the occurrence of defined diagnoses in cases versus controls. Statistical analysis and data management were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA).

RESULTS

We identified 5589 individuals (69.1% females, n=3862), mean age 47 years (47-48) who met the inclusion criteria for cases. These individuals were matched with 47,561 controls. Demographic details are presented in Supplementary Table 2.

The prevalence of the investigated respiratory symptoms and diagnoses is shown as odds ratio between PASC patients and matched controls for year 2019 (pre-pandemic), 12 months before PASC diagnosis, and 6 months after PASC diagnosis are shown Figure 2 for both sexes, and in Table 1 and Table 2 for females and males, respectively.

There was a higher prevalence of all studied diagnoses in cases in comparison with their matched controls both prior to and after the COVID-19 pandemic (Figure 2). Diagnoses with the highest significant odds ratio before the pandemic (2019) were acute upper respiratory tract infection (J06.9) and bronchitis (J20.9, J40.9) for both sexes, as well as dyspnea (R06.0) for males (Figure 2, Table 1-2). Diagnoses with the highest significant odds ratio 12 month before PASC were dyspnea (R06.0) and cough (R05) for both sexes, as well as other and unspecified respiratory disorders (R06.8) for females and bronchitis (J20.9, J40.9) for males.

As demonstrated for asthma (J45), with OR=1.95 for females and OR=1.76 for males in 2019, 3.76 for females and 4.18 for males 12 months before PASC diagnosis and 3.69 for females and 4.49 for males 6 months after PASC diagnosis.

The diagnoses with the highest significant OR 6 months after PASC diagnosis were dyspnea (R06.0) and other and unspecified respiratory disorders (R06.8) for both sexes, as well as asthma (J45.1, J45.8, J45.9, J46.9) for females and cough (R05) for males (Figure 2, Table 1-2).

Most of the diagnoses exhibited significantly higher odds ratios, both among females and males 12 months prior to the PASC diagnosis. It should be noted at this particular timepoint, many of the subjects may have developed PASC, but have not yet received their diagnosis. Moreover, the odds ratios for the time point 6 months after PASC diagnosis were in general lower compared with the period prior to PASC diagnosis (Figure 2, Table 1-2).

DISCUSSION

In this study, we found that individuals who developed PASC after SARS-CoV-2 infection had more respiratory illnesses and symptom diagnoses prior to the primary SARS-CoV-2 infection compared to matched controls. In 2019, more individuals that later developed PASC had acute upper respiratory tract infection, asthma or bronchitis than their controls. Frequencies of acute upper respiratory tract infection, asthma and bronchitis were higher in both males and females in the PASC group compared to controls 12 months prior to PASC diagnosis, while we observed lower frequencies of these diagnoses were observed 6 months after PASC diagnosis compared to controls.

Our study corroborates previous findings that PASC is more prevalent among females and is significantly associated with pre-existing conditions like asthma. Nearly two third of patients with PASC were females, aligning with existing literature on the higher prevalence of PASC among females, both in hospitalized and non-hospitalized patients (16-20). Furthermore, our study highlights that individuals with PASC had higher prevalence of various respiratory comorbidities compared with matched controls, even prior to the COVID-19 pandemic and their primary SARS-CoV-2 infection. We found significantly higher odds ratios of asthma among PASC cases compared to controls, both before and after the PASC diagnosis. Female sex and asthma as risk factors for PASC are supported by a previous study coordinating analyses of survey data and electronic records from the UK (16). Moreover, comorbid conditions like asthma as well as a history of healthcare usage were more strongly associated with PASC development in nonhospitalized individuals than in those who had been hospitalized (19). A recently published nationwide observational study utilizing Swedish registries with matched controls also identified the female sex as a risk of being diagnosed with PASC. Hanna et al. selected all individuals with a positive COVID-19 diagnosis between February 2020 and May 2021, subsequently examining additional diagnoses. However, nationwide access to primary care data was not available, and various healthcare registries were followed instead. Besides female sex, the most common symptoms and diagnostic codes (ICD-10 R-chapter (6)) for healthcare visits associated with PASC were dyspnea, abnormal findings on pulmonary diagnostic imaging, and chest pain (21). Our study showed similar findings even in the primary care context.

medRxiv preprint doi: https://doi.org/10.1101/2024.06.07.24308594; this version posted November 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Patients with PASC have higher proportions of prepandemic respiratory illnesses compared to controls and appear to be a vulnerable group susceptible to diverse respiratory conditions prior to pandemic. There are several possible explanations for the association between prepandemic respiratory illness and later diagnosis of PASC. Residual predisposition to acute and chronic inflammatory diseases might be a common pathway for developing both respiratory illnesses and PASC. An impaired immune response to respiratory pathogens might promote chronic conditions like asthma and PASC (22). Finally, the cumulative effect of prior infections and inflammatory conditions in the respiratory tract might trigger the PASC cascade. Importantly, the relative incidence of respiratory illnesses in individuals with PASC compared to their controls did not increase following the onset of PASC. Thus, PASC does not seem to be a specific factor that promotes asthma or more frequent acute respiratory tract infections. This is somewhat counterintuitive, as symptoms like cough and dyspnoea are often associated with the broad range of PASC symptpms. Instead, some patients who developed PASC may have borne an innate or aquired chronic illness susceptibility prior to the pandemic. The nature of this susceptibility has not been sufficiently explored yet, and future studies may shed more light (9).

The large, population-based cohort and comprehensive healthcare data presented here offer significant strengths, and the matching of cases and controls based on age, sex and socioeconomical area minimizes potential confounding bias. However, our study has limitations that warrant consideration. We used a retrospective study design, yet all diagnoses were registered prospectively in the register we used, limiting information bias regarding the ascertainment of diagnoses. In addition, PASC was a newly established diagnosis at the time, leading to an underdiagnosis due to a lag in clinical practice. Furthermore, the constraints on the heathcare apparatus during the on-going pandemic made acces to health care limited for individuals affected by PASC, posing the risk of including un-diagnosed individuals with PASC in the control group simply, due to the fact that they were not yet diagnosed correctly.

To properly diagnose asthma, healthcare providers should offer patients a dynamic spirometry test, which is essential for both assessing lung function and ensuring longterm asthma management (23). The COVID-19 pandemic has had a negative impact on asthma care, with around 25% fewer registrations of asthma and COPD patients in the Swedish Respiratory Registry in 2020 compared to 2019. This suggests that many patients did not receive the necessary spirometry testing, likely due to the reallocation of healtcare resources and the shift to digital follow-up visits. According to the Respiratory Registry, individuals with asthma and

COPD did not receive the expected level of evaluations and follow-ups, resulting in fewer asthma diagnoses. The reduced use of spirometry may also be attributed to COVID-19 related guidelines advising against such tests (24). Globally, the pandemic caused major disruptions in healthcare systems, altering guidelines, medical procedures and patient interactions. These changes likely contributed to delays in medical assessments and diagnoses, leading to underdiagnoses. The lack of in-person visits, particularly in primary care, may have further delayed new diagnoses, and this trend could have extended to other symptoms recorded later, as healthcare providers adapted to new protocols. It is also important to recognize that this analysis is based on electronic health records, which often focus on specific reasons for visits and may not fully reflect a patients overall health status.

Previous experiences from influenza pandemics, such as the H1N1 outbreak, indicated that patients with asthma were at a higher risk for severe illness, including hospitalization. This created a concern at the onset of the COVID-19 pandemic. However, early findings suggested that a diagnosis of asthma alone did not increase the risk of SARS-CoV-2 infection or the severity of COVID-19 outcomes. There is growing evidence that different asthma phenotypes play a significant role in assessing the risk of SARS-CoV-2 infection and severity of illness. Studies suggest that Th2-high inflammation may actually lower the likelihood of infection and severe outcomes, while Th2-low asthma may be linked to an elevated risk (22-24).

Our study, however, shows that asthma is associated with a higher risk of persistent symptoms after the initial COVID-19 infection, leading to the development of PASC. This suggests that while asthma may not be a significant driver of acute COVID-19 severity, it is a critical factor in longterm complications related to PASC.

Conclusions

Our study demonstrates that individuals with asthma are more likely to develop PASC, even if asthma does not increase the severity of acute COVID-19. These findings emphasize the need for future research to explore the specific mechanisms linking asthma to PASC and to identify at-risk populations for targeted interventions. Understanding the long-term consequences of COVID-19 in individuals with pre-existing conditions will be crucial for refining clinical management strategies and improving patient outcomes.

Conflicts of Interest

None of the authors report any conflicts of interest.

Funding

Funding was received from Region Stockholm FoUI-97300 (ACC), the Swedish Heart-lung foundation (ÅMW), and the Swedish Research Council (ÅMW).

Author contributions

Study design and conception: PL, ACC, GL, SL, ÅMW

Data acquisition: ACC

Quality control of data and algorithms: GL and ACC

Data analysis and interpretation: all authors

Statistical analysis: GL, PL

Manuscript preparation: PL, ACC, ÅW, IK

Funding and infrastructure: ÅMW, ACC

Manuscript editing: all authors

Manuscript review: all authors

medRxiv preprint doi: https://doi.org/10.1101/2024.06.07.24308594; this version posted November 12, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk 1. factors, and management. Bmj. 2021;374:n1648.

Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et 2. al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15.

Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. 3. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. Jama. 2021;325(19):2015-6.

Davis HE, McCorkell L, Vogel JM, Topol EJ. Author Correction: Long 4. COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(6):408.

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, 5. mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-46.

Organization WH. International Statistical Classification of Diseases and 6. Related Health Problems (ICD) [Internet]. World Health Organization; [Available from: https://www.who.int/standards/classifications/classification-of-diseases.

National Institute for Health and Care Excellence: Clinical Guidelines. COVID-7. 19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2020.; 2020.

Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition 8. of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e7. Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, et al. 9.

Long COVID science, research and policy. Nat Med. 2024.

10. Vrettou CS, Mantziou V, Vassiliou AG, Orfanos SE, Kotanidou A, Dimopoulou I. Post-Intensive Care Syndrome in Survivors from Critical Illness including COVID-19 Patients: A Narrative Review. Life (Basel). 2022;12(1).

11. Augustin M, Stecher M, Wüstenberg H, Di Cristanziano V, Sandaradura de Silva U, Picard LK, et al. 15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study. Front Immunol. 2023;14:1226622.

Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, et 12. al. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clin Infect Dis. 2023;76(3):e60-e70.

13. Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G. High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health. 2013;13:670.

Douglas L, Szatkowski L. Socioeconomic variations in access to smoking 14. cessation interventions in UK primary care: insights using the Mosaic classification in a large dataset of primary care records. BMC Public Health. 2013;13:546.

15. Sharma A, Lewis S, Szatkowski L. Insights into social disparities in smoking prevalence using Mosaic, a novel measure of socioeconomic status: an analysis using a large primary care dataset. BMC Public Health. 2010;10:755.

Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. 16. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;4(7):e532-e41.

17. Wallensten J, Ljunggren G, Nager A, Wachtler C, Petrovic P, Carlsson AC. Differences in psychiatric comorbidity patterns in patients diagnosed with chronic stressinduced exhaustion disorder and depression - A cohort study in the total population of Region Stockholm. J Affect Disord. 2024;351:765-73.

Kisiel MA, Lee S, Malmquist S, Rykatkin O, Holgert S, Janols H, et al. 18. Clustering Analysis Identified Three Long COVID Phenotypes and Their Association with General Health Status and Working Ability. J Clin Med. 2023;12(11).

Hedberg P, Granath F, Bruchfeld J, Askling J, Sjöholm D, Fored M, et al. Post 19. COVID-19 condition diagnosis: A population-based cohort study of occurrence, associated factors, and healthcare use by severity of acute infection. J Intern Med. 2023;293(2):246-58.

Zheng B, Daines L, Han O, Hurst JR, Pfeffer P, Shankar-Hari M, et al. 20. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis. European Respiratory Review. 2022;31(166):220071.

Hanna MO, Osvaldo F-R, Ida Henriette C, Sebastian K, Johan N, Lill T, et al. 21. How do clinicians use post-COVID syndrome diagnosis? Analysis of clinical features in a Swedish COVID-19 cohort with 18 monthsâ€[™] follow-up: a national observational cohort and matched cohort study. BMJ Public Health. 2024;2(1):e000336.

Gerayeli FV, Eddy RL, Sin DD. A proposed approach to pulmonary long 22. COVID: a viewpoint. Eur Respir J. 2024;64(3).

REPORT GM. 2022 GINA Report, Global Strategy for Asthma Management 23. and Prevention 2022 [20240513]. Available from: https://ginasthma.org/gina-reports/.

24. Health TNBoSAa. Covid-19-pandemins påverkan på följsamheten till Nationella riktlinjer. 2021.

Figures




Figure 1. Study design of cases and controls and the different study periods. Patients diagnosed with PASC (n=5589) were matched 1:10 with non-PASC controls (n=47561) and data were retrospectively retrieved for the pre-pandemic period (year 2019), and period prior to PASC diagnosis date (12 months).




Figure 2. Summary of the association between investigated respiratory symptoms and diagnoses in relation to PASC. The odds ratios (OR) and 99% CI are presented for females and males respectively in 2019, 12 months prior to PASC diagnosis and 6 months after PASC diagnosis.

TABLES

Table 1. Association between PASC and respiratory system diagnoses in women shown as odds ratios in the year 2019, 12 months before PASC diagnosis, and 6 months after the PASC diagnosis. Female included Cases n=3862, Controls n=32151.

Diagnosis	Year 2019	12 months pre-PASC diagnosis	6 months post- PASC diagnosis
Acute bronchitis	2.15	5.48	2.33
J20.9, J40.9	(1.60-2.90)	(3.60-8.33)	(1.15-4.72)
Acute upper	2.22	5.87	3.15
respiratory tract infection J06.9	(1.93-2.56)	(4.89-7.05)	(2.23-4.43)
Asthma J45.1,	1.95	3.76	3.69
J45.8, J45.9, J46.9	(1.58-2.41)	(3.13-4.51)	(2.91–4.68)
Cough R05	1.78	6.06	3.16
	(1.43-2.21)	(5.02-7.31)	(2.35-4.26)
Dyspnea R06.0	1.94	14.9	11.7
	(1.35-2.80)	(12.54-17.64)	(9.14-15.03)
Other and	3.34	18.8	9.80
unspecified respiratory disorders R06.8	(0.96-11.57)	(7.94-44.4)	(2.34-41.11)

Table 2. Association between PASC and respiratory system diagnoses in men shown as OR and 99% CI in the year 2019, 12 months before the PASC diagnosis, and 6 months after the PASC diagnosis. Male included Cases n=1727, Controls n=15410.

Diagnosis	Year 2019	12 months pre- PASC diagnosis	6 months post-PASC diagnosis
Acute bronchitis J20.9, J40.9	2.71	7.86	2.48
	(1.62-4.54)	(4.02-15.37)	(0.67-9.12)
Acute upper respiratory tract	2.47	6.60	4.22
infection J06.9	(1.89-3.23)	(4.71-9.27)	(2.36-7.56)
Asthma J45.1, J45.8, J45.9, J46.9	1.76	4.18	4.49
	(1.19-2.58)	(3.07-5.70)	(2.99–6.73)
Cough R05	1.64	7.90	4.62
	(1.12-2.42)	(5.92-10.55)	(2.93-7.31)
Dyspnea R06.0	1.89	15.62	12.86
	(0.98-3.65)	(11.91-20.50)	(8.60-19.25)
Other and unspecified respiratory	0	3.34	9
disorders R06.8		(0.74-15.08)	(1.45-55.70)

Supplementary Tables

Code	Diagnosis
J06.9	Acute upper respiratory tract infection
J20.9	Acute bronchitis
J40.9	Bronchitis unspecified as acute or chronic
J45.1	Non-allergic asthma
J45.8	Mixed asthma
J45.9	Asthma, unspecified
J46.9	Acute severe asthma
R05	Cough
R06.0	Dyspnea
R06.8	Other and unspecified respiratory disorders

Supplementary Table 1. ICD-10 diagnoses extracted from VAL database (13)

Supplementary Table 2. Median age, and the number of cases and controls based on sex.

Gender	Group	Ν	Median, years
Female	Case	3 862	47
Male	Case	1 727	48
Female	Control	32 151	47
Male	Control	15 410	47

Supplementary Table 3. The frequency of all studied diagnoses in the year 2019, 12 months before, and 6 months after the PASC diagnosis. Female included Cases n=3 862, Controls n=32 151.

Diagnoses	Females year 2019		Females 12 months prior to PASC diagnosis		Females 6 months after PASC diagnosis	
Acute upper respiratory tract infection J06.9	461 (11.9%)	1852 (5.6%)	349 (9.04%)	535 (1.66%)	79 (2.05%)	212 (0.66%)
Asthma J45.1, J45.8, J45.9, J46.9	193 (5%)	845 (2.63%)	306 (7.92%)	722 (2.25%)	174 (4.51%)	407 (1.27%)
Cough R05	178 (4.61%)	849 (2.964%)	334 (8.65%)	497 (1.55%)	106 (2.74%)	284 (0.88%)
Acute bronchitis J20.9, J40.9	96 (2.49%)	376 (1.17%)	63 (1.63%)	97 (0.3%)	17 (0.44%)	61 (0.19%)
Dyspnea R06.0	62 (1.61%)	268 (0.83%)	621 (16.08%)	409 (1.27%)	258 (6.68%)	195 (0.61%)
Other and unspecified respiratory disorders R06.8	6 (0.16%)	15 (0.05%)	29 (0.75%)	13 (0.04%)	7 (0.18%)	6 (0.02%)

Supplementary Table 4. The frequency of all studied diagnoses in the year 2019, 12 months before, and 6 months after the PASC diagnosis. Male included Cases n=1727, Controls n=15410.

Diagnoses	Males year 2019		Males 12 month prior to PASC diagnosis		Males 6 month after PASC diagnosis	
Acute upper respiratory tract infection J06.9	126 (7.30%)	474 (3.08%)	103 (5.96%)	146 (0.95%)	29 (1.68%)	62 (0.40%)
Asthma J45.1, J45.8, J45.9, J46.9	55 (3.18%)	281 (1.82%)	105 (6.08%)	234 (1.52%)	62 (3.59%)	126 (0.82%)
Cough R05	54 (3.36%)	294 (1.91%)	154 (8.92%)	189 (1.23%)	49 (2.84%)	96 (0.62%)
Acute bronchitis J20.9, J40.9	33 (1.91%)	109 (0.71%)	28 (1.62%)	32 (0.21%)	5 (0.29%)	18 (0.12%)
Dyspnea R06.0	19 (1.10%)	89 (0.58%)	244 (14.13%)	161 (1.04%)	100 (5.79%)	73 (0.47%)
Other and unspecified respiratory disorders R06.8	0 (0%)	4 (0.03%)	4 (0.23%)	11 (0.07%)	4 (0.23%)	4 (0.03%)